ArticleBiochemical genetics2026
Saikosaponin D Attenuates Postherpetic Neuralgia and Reduces Inflammation by Regulating Gut Microbiota in a Rodent Model.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Saikosaponin D (SSD) is a triterpenoid saponin derived from Bupleuri Radix and has therapeutic potential for the treatment of neuropathic pain. This study investigates the roles and underlying mechanisms of SSD in cellular and mouse models of resiniferatoxin (RTX)-induced postherpetic neuralgia (PHN). C57BL/6 mice were randomly assigned into four groups: control, RTX, RTX + vehicle, and RTX + SSD. Mechanical and thermal sensitivity were assessed to evaluate pain behaviors. Gut microbiota was depleted using antibiotic treatment, and fecal microbiota transplantation was used to restore gut flora in RTX-treated mice that received either vehicle or SSD. In vitro, RTX-stimulated human neuroblastoma SH-SY5Y cells were used as a cellular model of PHN. TRPA1 expression levels in mouse dorsal root ganglion and SH-SY5Y cells were measured by RT-qPCR and immunofluorescence staining. The levels of proinflammatory cytokines were evaluated in serum samples and SH-SY5Y cells via RT-qPCR or ELISA. Western blot was performed to assess protein levels of genes involved in TLR4/NF-κB and JAK/STAT3 pathways. Results showed that SSD attenuated RTX-induced neuralgia in mice. In both in vitro and in vivo models, SSD significantly reduced TRPA1 expression and proinflammatory cytokine levels. The protective effects of SSD against neuralgia were abolished following antibiotic-mediated gut microbiota depletion in mice. Fecal microbiota transplantation from SSD-treated mice alleviated RTX-induced neuralgia and inflammation in PHN model mice. Moreover, SSD reduced TLR4 protein level and reduced phosphorylation ratios of NF-κB p65, STAT3, and JAK in the lumbar spinal cord of RTX-treated mice and in SH-SY5Y cells. In conclusion, SSD alleviates RTX-induced PHN and inflammation in mice by modulating gut microbiota via the TLR4/NF-κB and JAK/STAT3 pathways.
Indexed as
Identifiers
42101756What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.